A Phase II study of gemcitabine in patients with malignant pleural mesothelioma Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Mesothelioma
  • Pleural Neoplasms

abstract

  • At the prescribed dosage and schedule, single agent gemcitabine appears to have limited activity in chemotherapy-naive patients with malignant pleural mesothelioma.

publication date

  • June 15, 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S

PubMed ID

  • 10375105

Additional Document Info

start page

  • 2577

end page

  • 82

volume

  • 85

number

  • 12